CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Pharmaceutical Group has announced that their pioneering mRNA-LNP-based CAR-T Cell Injection, SYS6020, received approval for clinical trials in China for systemic lupus erythematosus (SLE), following its prior approval for multiple myeloma. This innovative therapy, which targets B-cell maturation antigen, shows promise in providing a new, effective, and safer treatment option for SLE patients, with the added benefits of cost efficiency and minimal side effects.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
